Facebook
Instagram
Linkedin
Pinterest
Twitter
Youtube
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Tag: Michael Nelson
Intrommune’s Peanut Allergy Toothpaste Therapy Reaches Phase 1 Clinical Trial Milestone
Dave Bloom
-
2023/07/27
The process known as Oral Mucosal Immunotherapy does not involve ingesting the allergen.
Intrommune’s Toothpaste Immunotherapy for Peanut Allergy Completes Phase 1 Enrollment
Dave Bloom
-
2022/10/28
Company is developing a patient-friendly treatment platform for peanut and other food allergies.
Peanut Allergy Immunotherapy Toothpaste Makes Strides Toward Phase 2 Trial
Dave Bloom
-
2022/04/06
Phase 1 study amended after two cohorts show no significant adverse events.
Food Allergy Toothpaste Therapy: Positive News from Ongoing Phase 1 Trial
Dave Bloom
-
2022/02/10
No significant adverse events in any patient during ongoing Phase 1 trial.
Toothpaste Therapy for Food Allergies Takes Another Step Forward
Dave Bloom
-
2021/02/05
FDA accepts IND application by Intrommune Therapeutics.
Intrommune’s Food Allergy Toothpaste Therapy to Advance to Clinical Trials
Dave Bloom
-
2020/01/14
See the interview with the CEO as well as a new video describing the therapy here.
Patent Granted for Toothpaste Immunotherapy for Food Allergy
News Wire ~ 3rd Party Press Release
-
2019/03/11
The patent includes claims to the approach of combining allergenic proteins with toothpaste.
Company Developing Peanut Immunotherapy Toothpaste Meets with FDA
News Wire ~ 3rd Party Press Release
-
2018/09/06
"INT301 has the potential to be the first allergy immunotherapy treatment that easily integrates into a person’s daily routine."